Dr. Corey S. Cutler, M.D.
Hematology (Hematology (Internal Medicine) Physician)
44 Binney Street/d1b30, Dana-farber Cancer Institute
Boston, MA 02115
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 111
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
MA license 158280
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 111
- Services billed
- 300
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 188 | 86 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 132 | 29 |
| Established patient office or other outpatient visit, 40-54 minutes | 21 | 19 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 85 |
| Rezurock (belumosudil mesylate) | 49 |
| Atovaquone | 28 |
| Acyclovir Other prescribers in Boston, MA | 22 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Boston, MA | 21 |
| Tacrolimus Other prescribers in Boston, MA | 19 |
| Ursodiol Other prescribers in Boston, MA | 15 |
| Lorazepam Other prescribers in Boston, MA | 14 |
| Iclusig (ponatinib hcl) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 42 payments worth $81,508 in total to this clinician.
| Sanofi-aventis U.S. LLC | $29,848 |
|---|---|
| Sanofi US Services Inc. | $21,262 |
| Genzyme Corporation | $17,841 |
| Incyte Corporation | $6,998 |
| Csl Behring | $3,312 |
| Ipsen Innovation | $910 |
| Genetix Biotherapeutics Inc | $419 |
| Jazz Pharmaceuticals Inc. | $313 |
| Compensation for services other than consulting (speaking, faculty) | $38,761 |
|---|---|
| Consulting Fee | $22,735 |
| Travel and Lodging | $18,062 |
| Food and Beverage | $1,950 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi-aventis U.S. LLC Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty) REZUROCK · Oncology | $12,276 |
| Genzyme Corporation Mar 31, 2025 | Travel and Lodging travel to Firenze, Italy · in-kind | $8,590 |
| Sanofi US Services Inc. Apr 28, 2025 | Travel and Lodging REZUROCK · Oncology · travel to Paris, France · in-kind | $7,341 |
| Sanofi-aventis U.S. LLC Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,580 |
| Sanofi-aventis U.S. LLC Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) REZUROCK · Oncology | $5,022 |
| Sanofi US Services Inc. Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,022 |
| Genzyme Corporation Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,431 |
| Genzyme Corporation Oct 18, 2025 | Consulting Fee | $3,720 |
| Incyte Corporation Dec 18, 2025 | Consulting Fee Niktimvo · Oncology | $3,425 |
| Incyte Corporation Jul 31, 2025 | Consulting Fee Niktimvo · Oncology | $3,425 |
All 28 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Dec 18, 2025 | Consulting Fee Niktimvo · Oncology | $3,425 |
| Genzyme Corporation Oct 18, 2025 | Consulting Fee | $3,720 |
| Genzyme Corporation Oct 18, 2025 | Travel and Lodging travel to Detroit, MI · in-kind | $410 |
| Genzyme Corporation Oct 18, 2025 | Travel and Lodging travel to Detroit, MI · in-kind | $275 |
| Genzyme Corporation Oct 18, 2025 | Travel and Lodging travel to Detroit, MI | $69.00 |
| Ipsen Innovation Oct 10, 2025 | Consulting Fee | $910 |
| Sanofi-aventis U.S. LLC Oct 6, 2025 | Consulting Fee | $233 |
| Sanofi US Services Inc. Sep 3, 2025 | Consulting Fee REZUROCK · Oncology | $1,860 |
| Sanofi US Services Inc. Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,215 |
| Sanofi US Services Inc. Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,215 |
| Sanofi-aventis U.S. LLC Aug 4, 2025 | Consulting Fee | $1,854 |
| Sanofi-aventis U.S. LLC Aug 4, 2025 | Consulting Fee | $927 |
| Incyte Corporation Jul 31, 2025 | Consulting Fee Niktimvo · Oncology | $3,425 |
| Csl Behring May 16, 2025 | Consulting Fee | $3,312 |
| Sanofi-aventis U.S. LLC Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty) REZUROCK · Oncology | $12,276 |
| Sanofi US Services Inc. Apr 28, 2025 | Travel and Lodging REZUROCK · Oncology · travel to Paris, France · in-kind | $7,341 |
| Sanofi US Services Inc. Apr 28, 2025 | Travel and Lodging REZUROCK · Oncology · travel to Paris, France · in-kind | $345 |
| Sanofi US Services Inc. Apr 28, 2025 | Travel and Lodging REZUROCK · Oncology · travel to Paris, France · in-kind | $263 |
| Genzyme Corporation Mar 31, 2025 | Travel and Lodging travel to Firenze, Italy · in-kind | $8,590 |
| Genzyme Corporation Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,431 |
| Genzyme Corporation Mar 31, 2025 | Travel and Lodging travel to Firenze, Italy · in-kind | $115 |
| Sanofi-aventis U.S. LLC Mar 22, 2025 | Consulting Fee | $3,069 |
| Sanofi-aventis U.S. LLC Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,580 |
| Sanofi-aventis U.S. LLC Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) REZUROCK · Oncology | $5,022 |
| Sanofi US Services Inc. Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,022 |
| Sanofi-aventis U.S. LLC Jan 30, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $298 |
| Sanofi-aventis U.S. LLC Jan 30, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $293 |
| Sanofi-aventis U.S. LLC Jan 30, 2025 | Travel and Lodging travel to Dallas, TX | $62.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $4,570,218 in research payments for these studies, mostly to the institutions running them.
- An Open-Label, Phase 2 Study to Evaluate the Activity of Belumosudil in Subjects with New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell Transplantation
Sanofi-aventis U.S. LLC - A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
Sanofi US Services Inc. · Active, not recruiting · NCT06143891 - AGAVE-201, a phase 2, open-label, randomized, multicenter study to evaluate the efficacy, safety and tolerability of axatilimab at 3 different doses in patients with recurrent or refractory active chronic graft versus…
Syndax Pharmaceuticals, Inc. - A study to evaluate vimseltinib in adults with active chronic graft-versus-host disease (cgvhd)
Deciphera Pharmaceuticals Inc. - A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.